Press Releases

Mar 2, 2020

FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

* Sarclisa in combination with pomalidomide and dexamethasone (pom-dex) significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial
Feb 28, 2020

Sanofi US reaches settlement agreement to resolve allegations related to patient assistance
Feb 18, 2020

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

- Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi's well-established recombinant technology platform to expedite a potential COVID-19 vaccine
Feb 6, 2020

Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
- Photos 5
Jan 30, 2020

Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency

- Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threatening disease for which no treatments are approved

Show per page